Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Phosphomannose isomerase (PMI) deficiency is the cause of a new type of carbohydrate-deficient glycoprotein syndrome (CDGS). The disorder is caused by mutations in the PMI1 gene. The clinical phenotype is characterized by protein-losing enteropathy, while neurological manifestations prevailing in other types of CDGS are absent. Using standard diagnostic procedures, the disorder is indistinguishable from CDGS type Ia (phosphomannomutase deficiency). Daily oral mannose administration is a successful therapy for this new type of CDG syndrome classified as CDGS type Ib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphomannomutase deficiency is a cause of carbohydrate‐deficient glycoprotein syndrome type I
(1995) · FEBS Letters · doi:10.1016/0014-5793(95)01357-1 · Cited by 359 · cited 6×
“ing to a procedure by van Schaftingen and Jaeken (6).”
BackgroundMethodInfluentialJaeken, J., Vanderschueren-Lodeweyckx, M., Casaer, P., Snoeck, L., Corbeel, L., Eggermont, E., & Eeckels, R. (1980) · Pediatric Research · doi:10.1203/00006450-198002000-00117 · Cited by 287 · cited 1×
“(1) Hexokinase; (2) glucose 6-phosphate dehydrogenase; (3) phosphoglucose isomerase; (4) phosphomannose isomerase; (5) phosphomannomutase; (6) GDPmannose synthase.”
Panneerselvam, K., & Freeze, H. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118570 · Cited by 146 · cited 1×
“Based on studies showing that mannose could correct abnormal glycosylation in CDGS type Ia fibroblasts (15), mannose therapy was initiated and followed up for 11 mo.”
BackgroundSelf-citationThe X-ray crystal structure of phosphomannose isomerase from Candida albicans at 1.7 Å resolution
Cleasby, A., Wonacott, A. J., Skarzynski, T. J., Hubbard, R. E., Davies, G. J., Proudfoot, A. E. I., Bernard, A. R., Payton, M. A., & Wells, T. N. C. (1996) · Nature Structural Biology · doi:10.1038/nsb0596-470 · Cited by 115
Alton, G., Kjærgaard, S., Etchison, J. R., Skovby, F., & Freeze, H. H. (1997) · Biochemical and Molecular Medicine · doi:10.1006/bmme.1997.2574 · Cited by 111 · cited 1×
“In accordance with previous human ingestion studies (19), mannose was given orally in an initial dose of 100 mg/kg body wt three times a day.”
Self-citationCarbohydrate-Deficient Glycoprotein Syndrome - A Fourth Subtype
Stibler, H., Stephani, U., & Kutsch, U. (1995) · Neuropediatrics · doi:10.1055/s-2007-979762 · Cited by 92 · cited 1×
“(1) Hexokinase; (2) glucose 6-phosphate dehydrogenase; (3) phosphoglucose isomerase; (4) phosphomannose isomerase; (5) phosphomannomutase; (6) GDPmannose synthase.”
Purification cDNA cloning and heterologous expression of human phosphomannose isomerase
PROUDFOOT, A. E. I., TURCATTI, G., WELLS, T. N. C., PAYTON, M. A., & SMITH, D. J. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb19954.x · Cited by 86 · cited 3×
“The sequence of the human PMI cDNA (10) was used to design primers for PCR amplification.”
BackgroundMethodInfluentialCarbohydrate-Deficient Glycoprotein (CDG) Syndrome - A New Variant, Type III
Stibler, H., Westerberg, B., Hanefeld, F. A., & Hagberg, B. (1993) · Neuropediatrics · doi:10.1055/s-2008-1071513 · Cited by 71 · cited 1×
“(1) Hexokinase; (2) glucose 6-phosphate dehydrogenase; (3) phosphoglucose isomerase; (4) phosphomannose isomerase; (5) phosphomannomutase; (6) GDPmannose synthase.”
Human Fibroblasts Prefer Mannose over Glucose as a Source of Mannose for N-Glycosylation
Panneerselvam, K., Etchison, J. R., & Freeze, H. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.37.23123 · Cited by 70
Self-citationA novel Saccharomyces cerevisiae secretory mutant possesses a thermolabile phosphomannose isomerase
Payton, M. A., Rheinnecker, M., Klig, L. S., Detiani, M., & Bowden, E. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.6.2006-2010.1991 · Cited by 70 · cited 1×
“Phenotypic correction of the PMI deficiency in yeast was achieved by supplying 5 mM mannose together with glucose (20).”
Method
Cited by
Items 101–200 of 427
Mannose: a potential saccharide candidate in disease management
Dhanalakshmi, M., Sruthi, D., Jinuraj, K. R., Das, K., Dave, S., Andal, N. M., & Das, J. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03015-z · Cited by 62
“[55] studied phosphoMannose isomerase deficiency and Mannose therapy in CDG-lb (congenital disorder of glycosylation-1b) patients.”
BackgroundRind, N., Schmeiser, V., Thiel, C., Absmanner, B., Lübbehusen, J., Hocks, J., Apeshiotis, N., Wilichowski, E., Lehle, L., & Körner, C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq016 · Cited by 63
“Isoelectric focusing and SDS–PAGE of serum transferrin were carried out as described previously (15).”
Self-citationWestphal, V., Peterson, S. M., Patterson, M. C., Tournay, A. E., Blumenthal, A. L., Treacy, E. P., & Freeze, H. H. (2001) · Genetics in Medicine · doi:10.1097/00125817-200111000-00003 · Cited by 66
Self-citationCardiomyopathy in congenital disorders of glycosylation
Gehrmann, J., Sohlbach, K., Linnebank, M., Böhles, H., Buderus, S., Kehl, H.-G., Vogt, J., Harms, E., & Marquardt, T. (2003) · Cardiology in the Young · doi:10.1017/s1047951103000702 · Cited by 58
Self-citationBode, L., Eklund, E. A., MURCH, S. H., & Freeze, H. H. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00461.2004 · Cited by 64
“Also, mannose treatment of CDG-Ib patients relieves PLE (21) and improves HSPG staining (S.”
BackgroundSelf-citationBalancing N-linked glycosylation to avoid disease
Freeze, H. H., & Westphal, V. (2001) · Biochimie · doi:10.1016/s0300-9084(01)01292-5 · Cited by 64
Self-citationCline, A. E., Gao, N., Flanagan‐Steet, H. R., Sharma, V., Rosa, S., Sonon, R. N., Azadi, P., Sadler, K. C., Freeze, H. H., Lehrman, M. A., et al. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-05-0411 · Cited by 63
“Taken together, these results yield new insights into the cellular and molecular basis of type I CDGs, lend support to the concept of fluxbased therapy, and further highlight the utility of the zebrafish system in the investigation of inherited metabolic disorders.”
ResultSelf-citationSchollen, E., Frank, C. G., Keldermans, L., Reyntjens, R., Grubenmann, C. E., Clayton, P. T., WINCHESTER, B. G., Smeitink, J., Wevers, R. A., Aebi, M., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.016923 · Cited by 56
Metabolism and Health Impacts of Dietary Sugars
Alam, Y. H., Kim, R., & Jang, C. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.1.20 · Cited by 60
Eklund, E. A., Merbouh, N., Ichikawa, M., Nishikawa, A., Clima, J. M., Dorman, J. A., Norberg, T., & Freeze, H. H. (2005) · Glycobiology · doi:10.1093/glycob/cwj006 · Cited by 60
Self-citationMarquardt, T., & Freeze, H. (2001) · Biological Chemistry · doi:10.1515/bc.2001.024 · Cited by 54
“The normal human or mouse genes encoding PMI (MPI) restore mannose-independent growth to pmi40 strains (Proudfoot et al., 1994).”
BackgroundInfluentialSelf-citationCallewaert, N. (2003) · Glycobiology · doi:10.1093/glycob/cwg040 · Cited by 53
“The other known CDG-I subtypes (Ib to Ig) have been characterized on the genetic and enzymological level only recently; consequently, the number of reported patients is still low (Niehues et al., 1998; Burda et al., 1998; Korner et al., 1998, 1999; Imbach et al., 2000; Chantret et al., 2002).”
BackgroundMethodDevelopment of liver disease despite mannose treatment in two patients with CDG-Ib
Mention, K., Lacaille, F., Valayannopoulos, V., Romano, S., Kuster, A., Cretz, M., Zaidan, H., Galmiche, L., Jaubert, F., de Keyzer, Y., et al. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.08.126 · Cited by 52
Life with too much polyprenol: polyprenol reductase deficiency
Gründahl, J. E. H., Guan, Z., Rust, S., Reunert, J., Müller, B., Chesne, I. D., Zerres, K., Rudnik‐Schöneborn, S., Ortiz‐Brüchle, N., Häusler, M., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.12.017 · Cited by 50
“IMPP and SDS-Page was done as described [14].”
MethodSelf-citationMiyamoto, B. E., & Kakkis, E. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-49 · Cited by 60
“We identified 15 diseases having a relevant corresponding animal model, a treatment with a known mechanism, and a treatment effect which appeared to be potentially clinically relevant [26,43-56] (Table 1).”
BackgroundTowards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients
Freeze, H. H. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.01.004 · Cited by 63
“These children fail to thrive, have coagulopathies, proteinlosing enteropathy and liver fibrosis, and they show remarkable improvement when the therapy is initiated [28,29].”
BackgroundSelf-citationNiethamer, T. K., Yardeni, T., Leoyklang, P., Ciccone, C., Astiz-Martinez, A., Jacobs, K., Dorward, H. M., Zerfas, P. M., Gahl, W. A., & Huizing, M. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.10.011 · Cited by 54
Würde, A. E., Reunert, J., Rust, S., Hertzberg, C., Haverkämper, S., Nürnberg, G., Nürnberg, P., Lehle, L., Rossi, R., & Marquardt, T. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.01.001 · Cited by 50
Self-citationAnalysis of Glycosylation in CDG-Ia Fibroblasts by Fluorophore-assisted Carbohydrate Electrophoresis
Gao, N., Shang, J., & Lehrman, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500510200 · Cited by 56
Liu, H., Gu, R., Zhu, Y., Lian, X., Wang, S., Liu, X., Ping, Z., Liu, Y., & Zhou, Y. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320912661 · Cited by 52
“The cells were grouped as follows: (1) L-Man group, which received 25 mM D-mannose treatment as previously described,8,9 (2) H-Man group, which received 50 mM D-mannose treatment, and (3) CTRL (control) group, treated with maintenance medium only.”
MethodDiseases of abnormal protein glycosylation: an emerging area.
Kornfeld, S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3140 · Cited by 50
“In this issue of The Journal , Niehues and colleagues describe a young male patient with a protein losing enteropathy and recurrent thrombosis who has a new variant of the CDG syndrome (10).”
BackgroundMannose: A Sweet Option in the Treatment of Cancer and Inflammation
Nan, F., Sun, Y., Liang, H., Zhou, J., Ma, X., & Zhang, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877543 · Cited by 50
Free Sugar and Sugar Alcohol Concentrations in Human Breast Milk
Cavalli, C., Teng, C. C., Battaglia, F. C., & Bevilacqua, G. (2006) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/01.mpg.0000189341.38634.77 · Cited by 48
Sharma, V., Ichikawa, M., He, P., Scott, D. A., Bravo, Y., Dahl, R., Ng, B. G., Cosford, N. D. P., & Freeze, H. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.285502 · Cited by 51
Self-citationBöhles, H., Sewell, A., Gebhardt, B. R., Reinecke‐Lüthge, A., Klöppel, G., & Marquardt, T. (2001) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1013944308881 · Cited by 51
Self-citationDenecke, J., Kranz, C., von Kleist-Retzow, J.-C., Bosse, K., Herkenrath, P., Debus, O. M., Harms, E., & Marquardt, T. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000169963.94378.b6 · Cited by 55
“Transferrin was immunoprecipitated and stained as described previously (9).”
Self-citationSone, H., Shimano, H., Ebinuma, H., Takahashi, A., Yano, Y., Iida, K., Suzuki, H., Toyoshima, H., Kawakami, Y., Okuda, Y., et al. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00153-7 · Cited by 51
Miller, B. S., & Freeze, H. H. (2003) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1021883605280 · Cited by 53
“Mannose reverses hypoglycemia and deficient AT-III within a few weeks, and within 1-2 months plasma protein levels are normal and protein-losing enteropathy disappears [20,56,57].”
BackgroundSelf-citationCarbohydrate-deficient glycoprotein syndrome type II
Schachter, H., & Jaeken, J. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(99)00054-x · Cited by 48
Dahl, R. S., Bravo, Y., Sharma, V., Ichikawa, M., Dhanya, R.-P., Hedrick, M., Brown, B. T., Rascon, J., Vicchiarelli, M., Mangravita-Novo, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101401a · Cited by 47
Self-citationInsights into complexity of congenital disorders of glycosylation
Goreta, S. Š., Dabelić, S., & Dumić, J. (2012) · Biochemia Medica · doi:10.11613/bm.2012.019 · Cited by 59
“1), also known as phosphomannose isomerase (PMI), an enzyme which catalyzes the formation of mannose-6-phosphate from fructose-6-phosphate (Figure 1) (22).”
BackgroundFreeze, H. H., & Aebi, M. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(99)00072-1 · Cited by 55
Self-citationSchollen, E., DORLAND, L., de Koning, T. J., van Diggelen, O. P., Huijmans, J. G. M., Marquardt, T., Babovic‐Vuksanovic, D., Patterson, M. C., Imtiaz, F., WINCHESTER, B. G., et al. (2000) · Human Mutation · doi:10.1002/1098-1004(200009)16:3<247::aid-humu7>3.0.co;2-a · Cited by 46
Self-citationMetabolic manipulation of glycosylation disorders in humans and animal models
Freeze, H. H., & Sharma, V. (2010) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2010.03.011 · Cited by 52
Self-citationTreatment Options in Congenital Disorders of Glycosylation
Park, J. H., & Marquardt, T. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.735348 · Cited by 46
Self-citationMutational analysis of Sanfilippo syndrome type A (MPS IIIA): identification of 13 novel mutations
Beesley, C. E., Young, E. P., Vellodi, A., & WINCHESTER, B. G. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.9.704 · Cited by 48
Advances in analytical mass spectrometry to improve screening for inherited metabolic diseases
R�schinger, W., Olgem�ller, B., Fingerhut, R., Liebl, B., & Roscher, A. A. (2003) · European Journal of Pediatrics · doi:10.1007/s00431-003-1356-y · Cited by 43
“However, an efficient treatment, namely oral D-mannose, is available only for CDG type 1b that would warrant mass screening [ 50 ].”
BackgroundGenetic and metabolic liver disease
Thompson, R. J., Portmann, B. C., & Roberts, E. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00004-0 · Cited by 43
Babovic‐Vuksanovic, D., & O’Brien, J. F. (2007) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256251 · Cited by 48
Shang, J., Gao, N., Kaufman, R. J., Ron, D., Harding, H. P., & Lehrman, M. A. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200607007 · Cited by 42
“Because Ib is the only treatable subtype of the 12 CDG-Is (a–l; Niehues et al., 1998), the compensatory effects of DIS (Fig.”
BackgroundThe genetics of monogenic intestinal epithelial disorders
Babcock, S. J., Flores-Marín, D. L., & Thiagarajah, J. R. (2022) · Human Genetics · doi:10.1007/s00439-022-02501-5 · Cited by 45
MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If
Schenk, B., Imbach, T., Frank, C. G., Grubenmann, C. E., Raymond, G. V., Hurvitz, H., Raas-Rotschild, A., Luder, A. S., Jaeken, J., Berger, E. G., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13419 · Cited by 41
“Several subtypes of CDG have been characterized at the biochemical and genetic level, such as the deficiency in phosphomannomutase activity, caused by a defect in the PMM2 gene (CDG-Ia) (8, 9), the deficiency in the phosphomannose isomerase activity due to a mutated PMI locus (CDG-Ib) (10, 11), mutations in the ALG6 g…”
Pitkänen, J., Törmä, A., Alff-Tuomala, S., Huopaniemi, L., Mattila, P., & Renkonen, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410619200 · Cited by 40
Vasomodulating Potential of Mediterranean Wild Plant Extracts
Grande, S., Bogani, P., de Saizieu, A., Schueler, G., Galli, C., & Visioli, F. (2004) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf049436e · Cited by 40
Successful treatment of carbohydrate deficient glycoprotein syndrome type 1b with oral mannose
Hendriksz, C. J., McClean, P., Henderson, M. J., Keir, D. G., Worthington, V. C., Imtiaz, F., Schollen, E., Matthijs, G., & Winchester, B. G. (2001) · Archives of Disease in Childhood · doi:10.1136/adc.85.4.339 · Cited by 43
“These children have minimal neurological symptoms and suffer predominantly from gastrointestinal and hepatic disorders which appear to be reversible by supplementation of the diet with mannose.”
BackgroundNutrition interventions in congenital disorders of glycosylation
Boyer, S. W., Johnsen, C., & Morava, É. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.04.003 · Cited by 40
Drouin‐Garraud, V., Belgrand, M., Gr�newald, S., Séta, N., Dacher, J.-N., H�nocq, A., Matthijs, G., Cormier‐Daire, V., Fr�bourg, T., & Saugier-Véber, P. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1298 · Cited by 39
Regulation of dolichol-linked glycosylation
Welti, M. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9417-y · Cited by 52
Phosphomannomutase Deficiency: The Molecular Basis of the Classical Jaeken Syndrome (CDGS Type Ia)
Matthijs, G., Schollen, E., Heykants, L., & Grünewald, S. (1999) · Molecular Genetics and Metabolism · doi:10.1006/mgme.1999.2914 · Cited by 39
Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview
Sparks, S. E., & Krasnewich, D. M. (2017) · Europe PMC (PubMed Central) · Cited by 38
ALG1-CDG: A new case with early fatal outcome
Rohlfing, A.-K., Rust, S., Reunert, J., Tirre, M., Chesne, I. D., Wemhoff, S., Meinhardt, F., Hartmann, H., Das, A. M., & Marquardt, T. (2013) · Gene · doi:10.1016/j.gene.2013.10.013 · Cited by 38
Self-citationImpact of glycans on T‐cell tolerance to glycosylated self‐antigens
Purcell, A. W., van Driel, I. R., & Gleeson, P. A. (2008) · Immunology and Cell Biology · doi:10.1038/icb.2008.48 · Cited by 47
Pérez‐Cerdá, C., Quelhas, D., Vega, A. I., Ecay, M. J., Vilarinho, L., & Ugarte, M. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.093450 · Cited by 38
“Among the CDG-I group, CDG-Ib is peculiar because it is characterized by hepatointestinal symptoms without nervous system involvement ( 12 ).”
Cormier‐Daire, V., Amiel, J., Vuillaumier‐Barrot, S., TAN, J., Durand, G., Münnich, A., Merrer, M. F. L., & Séta, N. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.11.875 · Cited by 39
The intestinal glycome and its modulation by diet and nutrition
Kavanaugh, D. W., O’Callaghan, J., Kilcoyne, M., Kane, M., Joshi, L., & Hickey, R. M. (2015) · Nutrition Reviews · doi:10.1093/nutrit/nuu019 · Cited by 41
MPI depletion enhances O-GlcNAcylation of p53 and suppresses the Warburg effect
Shtraizent, N., DeRossi, C., Nayar, S., Sachidanandam, R., Katz, L. S., Prince, A., Koh, A. P., Vincek, A. S., Hadas, Y., Hoshida, Y., et al. (2017) · eLife · doi:10.7554/elife.22477 · Cited by 41
“Interestingly, MPI-CDG patients are treated with oral mannose supplementation, which corrects the majority, but not all, of their symptoms (de Lonlay and Seta, 2009, Niehues et al., 1998; Mention et al., 2008).”
BackgroundInfluentialSelf-citationDimitrov, B., Himmelreich, N., Ederveen, A. L. H., Lüchtenborg, C., Okun, J. G., Breuer, M., Hutter, A., Carl, M., Guglielmi, L., Hellwig, A., et al. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.01.008 · Cited by 39
Protein glycosylation—an evolutionary crossroad between genes and environment
Lauc, G., & Zoldoš, V. (2010) · Molecular BioSystems · doi:10.1039/c0mb00067a · Cited by 309
TMEM165 Deficiency: Postnatal Changes in Glycosylation
Althoff, S. S., Grüneberg, M., Reunert, J., Park, J. H., Rust, S., Mühlhausen, C., Wada, Y., Santer, R., & Marquardt, T. (2015) · JIMD Reports · doi:10.1007/8904_2015_455 · Cited by 36
Self-citationHelander, A., Jaeken, J., Matthijs, G., & Eggertsen, G. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.018 · Cited by 36
Limitations of galactose therapy in phosphoglucomutase 1 deficiency
Nolting, K., Park, J. H., Tegtmeyer, L. C., Zühlsdorf, A., Grüneberg, M., Rust, S., Reunert, J., Chesne, I. D., Debus, V., Schulze‐Bahr, E., et al. (2017) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2017.07.010 · Cited by 36
Self-citationWild Artichoke Prevents the Age-Associated Loss of Vasomotor Function
Rossoni, G., Grande, S., Galli, C., & Visioli, F. (2005) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf052499s · Cited by 36
Marquardt, T., Hülskamp, G., Gehrmann, J., Debus, V., Harms, E., & Kehl, H.-G. (2002) · European Journal of Pediatrics · doi:10.1007/s00431-002-1029-2 · Cited by 41
“In the patient’s leucocytes, PMM activity was undetectable and was lower than in 15 other CDG-Ia patients previously diagnosed with some residual activity under equivalent assay conditions (method [10], modified as described in [5]).”
MethodSelf-citationChu, J., Mir, A., Gao, N., Rosa, S., Monson, C., Sharma, V., Steet, R., Freeze, H. H., Lehrman, M. A., & Sadler, K. C. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.010116 · Cited by 36
“The first successful treatment of a 6-year-old MPI-CDG patient with oral mannose supplementation resulted in clinical response within 2 weeks and subsequent improvement in serum protein glycosylation pattern at 11-month follow up (Niehues et al., 1998).”
BackgroundMethodInfluentialSelf-citationEnns, G. M., Steiner, R. D., Buist, N. R. M., Cowan, C. A., Leppig, K. A., McCracken, M. F., Westphal, V., Freeze, H. H., O’Brien, J. F., Jaeken, J., et al. (2002) · The Journal of Pediatrics · doi:10.1067/mpd.2002.128658 · Cited by 36
Self-citationCell surface expression of C1qRP/CD93 is stabilized by O‐glycosylation
Park, M., & Tenner, A. J. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10332 · Cited by 40
“…of mechanistically distinct disorders including autoimmune disorders (Parekh et al., 1985; Watson et al., 1999; Demetriou et al., 2001; Rudd et al., 2001), inflammatory disease (Parekh et al., 1985; Malhotra et al., 1995), and metabolic disorders (Feramisco et al., 1973; Niehues et al., 1998).”
BackgroundCongenital hepatic fibrosis in 3 siblings with phosphomannose isomerase deficiency
de Koning, T. J., Nikkels, P. G. J., DORLAND, L., Bekhof, J., Schrijver, J. E. A. R. D., van Hattum, J., van Diggelen, O. P., Durán, M., Berger, R., & Poll‐The, B. T. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000185 · Cited by 35
“Recognition of congenital hepatic fibrosis and protein-losing enteropathy associated with PMI deficiency is important, as some of the clinical symptoms are potentially treatable with mannose therapy [18, 19 ].”
BackgroundInfluentialUsing heparin therapy to reverse protein-losing enteropathy in a patient with CDG-Ib
Liem, Y. S., Bode, L., Freeze, H. H., Leebeek, F. W. G., Zandbergen, A. A. M., & Wilson, J. H. P. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1061 · Cited by 35
“In patients with CDG-Ib, oral mannose therapy has been shown to reverse PLE”
BackgroundSelf-citationIGF system in children with congenital disorders of glycosylation
Miller, B. S., Khosravi, M. J., Patterson, M. C., & Conover, C. A. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03531.x · Cited by 35
Bode, L., & Freeze, H. H. (2005) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.11.004 · Cited by 36
Self-citationDiagnosis of congenital disorders of glycosylation type‐I using protein chip technology
Mills, K. A., Mills, P. B., Jackson, M., Worthington, V., Beesley, C. E., Mann, A., Clayton, P. T., Grünewald, S., Keir, G., Young, L., et al. (2006) · PROTEOMICS · doi:10.1002/pmic.200500682 · Cited by 35
Fructose and Mannose in Inborn Errors of Metabolism and Cancer
Lieu, E. L., Kelekar, N., Bhalla, P., & Kim, J. (2021) · Metabolites · doi:10.3390/metabo11080479 · Cited by 42
“With (1) N-glycosylation being one of the most abundant post-transitional modifications, and (2) the essential role of MPI in producing D-mannose derivatives [80], it is not surprising that complete loss of MPI causes embryonic lethality [81,82].”
BackgroundDancourt, J., Vuillaumier‐Barrot, S., de Baulny, H. O., Sfaello, I., Barnier, A., le Bizec, C., Dupré, T., Durand, G., Séta, N., & Moore, S. E. H. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000219430.52532.8e · Cited by 34
“As phosphomannomutase and phosphomannose isomerase cellular activities were found to be normal in patient MS (data not shown), CDG Ia and Ib, which are the most frequent CDG I subtypes, could be excluded (15,16).”
BackgroundMetabolic Mimics: The Disorders of N-Linked Glycosylation
Patterson, M. C. (2005) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2005.10.002 · Cited by 40
PMI (manA) as a nonantibiotic selectable marker gene in plant biotechnology
Stoykova, P., & Stoeva-Popova, P. (2010) · Plant Cell Tissue and Organ Culture (PCTOC) · doi:10.1007/s11240-010-9858-6 · Cited by 36
“In humans, mutations in the gene for PMI cause carbohydratedeficient glycoprotein syndrome type Ib; the serious clinical symptoms of this syndrome can be overcome by the oral administration of the carbohydrate mannose (Man) (Niehues et al. 1998).”
BackgroundSharma, V., Nayak, J., DeRossi, C., Charbono, A., Ichikawa, M., Ng, B. G., Grajales‐Esquivel, E., Srivastava, A., Wang, L., He, P., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-245514 · Cited by 33
Self-citationDeRossi, C., Bambino, K., Morrison, J. K., Sakarin, I., Villacorta-Martín, C., Zhang, C., Ellis, J. L., Fiel, M. I., Ybanez, M. D., Lee, Y. A., et al. (2019) · Hepatology · doi:10.1002/hep.30677 · Cited by 38
Alsharhan, H., He, M., Edmondson, A. C., Daniel, E. J. P., Chen, J., Donald, T., Bakhtiari, S., Amor, D. J., Jones, E. A., Vassallo, G., et al. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12378 · Cited by 38
Self-citationWestphal, V., Schottstädt, C., Marquardt, T., & Freeze, H. H. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3017 · Cited by 32
Self-citationCarbohydrate-deficient glycoprotein syndromes
Gordon, N. S. (2000) · Postgraduate Medical Journal · doi:10.1136/pmj.76.893.145 · Cited by 33
“reported on three children with normal phosphomannomutase activity and a deficiency of phosphomannose isomerase, two of whom presented with intestinal and liver disease. The first was normal on neurological examination, but died from an unknown cause at the age of four. The second had a similar clinical picture, mainl…”
DHPLC analysis as a platform for molecular diagnosis of congenital disorders of glycosylation (CDG)
Schollen, E., Martens, K., Geuzens, E., & Matthijs, G. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200858 · Cited by 32
Gao, H. X., Yu, Y., & Leary, J. A. (2005) · Analytical Chemistry · doi:10.1021/ac050549m · Cited by 31
Hardré, R., Khaled, A., Willemetz, A., Dupré, T., Moore, S. E. H., Gravier‐Pelletier, C., & Merrer, Y. L. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.074 · Cited by 35
A Novel Type of Macrothrombocytopenia Associated with a Defect in α2,3-Sialylation
Jones, C., Denecke, J., Sträter, R., Stölting, T., Schunicht, Y., Zeuschner, D., Klumperman, J., Lefeber, D. J., Spelten, O., Zarbock, A., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.012 · Cited by 31
“Transferrin was immunoprecipitated from serum and stained.(18) Isoelectric focusing was performed with a Phast electrophoresis system using a gel with a pH range of 5 to 7 (Pharmacia, Freiburg, Germany).”
MethodSelf-citationCongenital disorders of glycosylation (CDG): Update and new developments
Jaeken, J. (2004) · Journal of Inherited Metabolic Disease · doi:10.1023/b:boli.0000031221.44647.9e · Cited by 31
“An e⁄cient treatment for (only) one of the CDG (mannose in CDG-Ib; Niehues et al 1998).”
MethodModification of Glycosylation as A Therapeutic Strategy
WINCHESTER, B. G., & Fleet, G. W. J. (2000) · Journal of Carbohydrate Chemistry · doi:10.1080/07328300008544094 · Cited by 31
GMPPA defects cause a neuromuscular disorder with α-dystroglycan hyperglycosylation
Franzka, P., Henze, H., Jung, M. J., Schüler, S. C., Mittag, S., Biskup, K., Liebmann, L., Kentache, T., Morales, J. M., Martínez‐Benítez, B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139076 · Cited by 33
“Mutations in phosphomannomutase 2 (PMM2) (33), which converts mannose-6-phosphate to mannose-1-phosphate, and mutations in phosphomannose isomerase (PMI) (34), which facilitates the interconversion of fructose 6-phosphate and mannose-6-phosphate, decrease the availability of GDP-mannose and thus result in the hypoglyc…”
BackgroundSelf-citationGrünewald, S., Huyben, K. M. L. C., de Jong, J. G. N., Smeitink, J. A. M., Rubio, E., Boers, G. H. J., Conradt, H. S., Wendel, U., & Wevers, R. A. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(99)00078-2 · Cited by 30
Long term outcome of MPI‐CDG patients on D‐mannose therapy
Girard, M., Douillard, C., Debray, D., Lacaille, F., Schiff, M., Vuillaumier‐Barrot, S., Dupré, T., Fabrè, M., Damaj, L., Kuster, A., et al. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12289 · Cited by 38
Chemical Therapies for Congenital Disorders of Glycosylation
Sosicka, P., Ng, B. G., & Freeze, H. H. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00601 · Cited by 30
Self-citationVuillaumier‐Barrot, S., Bizec, C. L., de Lonlay, P., Barnier, A., Mitchell, G. A., Pelletier, V. A., Prevost, C., Saudubray, J., Durand, G., & Séta, N. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.11.849 · Cited by 31
van Ommen, C. H., Peters, M., Barth, P. G., Vreken, P., WANDERS, R. J. A., & Jaeken, J. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.103503 · Cited by 29
Woodley, K. T., Dillingh, L. S., Giotopoulos, G., Madrigal, P., Rattigan, K. M., Philippe, C., Dembitz, V., Magee, A. M. S., Asby, R., van de Lagemaat, L. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37652-0 · Cited by 35
Protein N-Glycosylation in Cardiovascular Diseases and Related Risk Factors
Gudelj, I., & Lauc, G. (2018) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-018-0579-4 · Cited by 30
Mouse models for congenital disorders of glycosylation
Thiel, C., & Körner, C. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9295-7 · Cited by 30
“As the MPI deficiency can be bypassed by oral mannose supplementation, remarkable clinical improvement occurs in the patients including reduction of hepatomegaly, normalization of growth, and normalization of the serum transferrin isoelectric focusing pattern, coagulation factors, and other biochemical parameters (Nie…”
BackgroundInfluentialSelf-citationLuo, J., Li, Y., Zhai, Y., Liu, Y., Zeng, J., Wang, D., Li, L., Zhu, Z., Chang, B. Y., Deng, F., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109378 · Cited by 30
Kotena, Z. M., Behjatmanesh‐Ardakani, R., & Hashim, R. (2014) · Liquid Crystals · doi:10.1080/02678292.2014.886731 · Cited by 27
“[3] Mannose and glucose are different from each other since they are epimers at the C2 position but, surprisingly, many of their physical behaviours are different.[4] In addition, there are two possible stereoisomers at the C1 position, two possible orientations (axial/equatorial) of the hydroxyl group, thus resulting…”
BackgroundKawanishi, K., Saha, S., Diaz, S. L., Vaill, M., Sasmal, A., Siddiqui, S. S., Choudhury, B., Sharma, K., Chen, X., Schoenhofen, I. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci137681 · Cited by 27
“Inherited deficiency of PMI results in congenital disorder of glycosylation, type Ib (CDG-Ib) (PMI-CDG) associated with protein loss in intestines, liver disease, hypoglycemia, and blood-clotting disorders (41), and these patients respond well to oral mannose therapy (42).”
Self-citationHaeuptle, M. A., Welti, M., Troxler, H., Hülsmeier, A. J., Imbach, T., & Hennet, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.165795 · Cited by 26
Gao, H. X., Chen, Y., & Leary, J. A. (2004) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2004.09.017 · Cited by 31
Metadata
- Authors
- Niehues, R., Hasilik, M., Alton, G., Körner, C., Schiebe-Sukumar, M., Koch, H. G., Zimmer, K. P., Wu, R., Harms, E., Reiter, K., von Figura, K., Freeze, H. H., Harms, H. K., & Marquardt, T.
- Affiliations
- University Hospital Münster (DE)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- University of Göttingen (DE)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-04-01
- Volume
- 101
- Issue
- 7
- Pages
- 1414-1420
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508719
- OpenAlex
- W1970122244
- Cited by
- 422
- References
- 20
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 13 · 2023: 11 · 2022: 8 · 2021: 14 · 2020: 16 · 2019: 7 · 2018: 12 · 2017: 12 · 2016: 4 · 2015: 13 · 2014: 18 · 2013: 7 · 2012: 14
- FWCI
- 22.32
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01gm049096-04)
- National Institute of General Medical Sciences (R01 GM49096)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- protein-losing enteropathy, phosphomannomutase deficiency
- MeSH terms
- Cells, Cultured, Glycoproteins, Glycosylation, Humans, Infant, Male, Mannose, Mannose-6-Phosphate Isomerase, Mutation, Protein Processing, Post-Translational, Protein-Losing Enteropathies, Syndrome, Transferrin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.